Genoptix called area's fastest-growing company
Oct. 11 (UNION-TRIBUNE)
Genoptix, a Carlsbad-based company that helps oncologists determine the proper treatment for people with blood cancers, topped a list of the region's fastest-growing companies compiled by the Deloitte & Touche accounting firm.
The firm's annual San Diego Technology Fast 50 award ranks technology, media, telecommunications and life-sciences companies by percentage of revenue growth over five years.
More Biotechnology News
Oct. 9 (UNION-TRIBUNE)
Will disease data change patients' habits?: Health officials and scientists have warned for years that diet and exercise play a role in preventing heart attacks and certain cancers. Yet Americans grow fatter.
NEW YORK, 8:27 a.m. Oct. 9 (REUTERS)J&J names surgical chief to lead pharmaceuticals: Johnson & Johnson appointed Sheri McCoy, leader of its surgical care group, Thursday worldwide chairman of its pharmaceuticals group, effective Jan. 1. NEW YORK, 5:31 a.m. Oct. 9 (REUTERS)
Mylan defends capital structure amid stock swoon: Generic drug maker Mylan Inc defended its capital structure Thursday and said it ”could hardly be in a stronger position” to weather the credit crisis, despite a 32 percent drop in its stock this month.
NEW YORK, 8:04 a.m. Oct. 8 (REUTERS)
Pharma, big biotech may avoid credit ills, report says: The credit crunch could prove to be a boon for large pharmaceutical and biotechnology companies based on their limited exposure to the debt markets, according to two reports from analysts.
WASHINGTON, 12:18 p.m. Oct. 7 (REUTERS)
Data show no stroke risk with Pfizer lung drug-FDA: Early data from a 4-year clinical trial show no increased risk of stroke in patients given Pfizer Inc's lung drug Spiriva compared with placebo, the Food and Drug Administration said Tuesday.
INDIANAPOLIS, 9:55 a.m. Oct. 7 (AP)
Eli Lilly settles Zyprexa inquiries in 32 states: Drugmaker Eli Lilly & Co. cleared another legal cloud hanging over its top-selling drug Zyprexa when it announced a $62 million settlement Tuesday, but several other storms are still brewing for the antipsychotic medication.
BOSTON, 5:40 a.m. Oct. 6 (REUTERS)
Eli Lilly agrees to buy ImClone for $6.5 billion: Eli Lilly and Co has agreed to acquire ImClone Systems Inc for $6.5 billion, potentially bringing to a close one of the most colorful corporate sagas in biotech history.
TRENTON, N.J., 5:55 a.m. Oct. 6 (AP)
J&J Crohn's disease drug is superior in its study: An injected Johnson & Johnson biologic drug used to treat several immune diseases controlled Crohn's disease, a difficult-to-treat bowel disorder, better than a widely used pill, a study found.
FRANKFURT/LONDON, 4:29 a.m. Oct. 2 (REUTERS)
European biotech gasps as funding well dries up: Europe's biotechnology industry, already lagging well behind the United States, faces an unprecedented funding squeeze that may drive some companies to the wall.
Sept. 30 (UNION-TRIBUNE)
Cardinal says it will spin off tech business, base it in S.D.: Bringing a glint of sunshine to an otherwise gloomy day for the economy, Cardinal Health announced yesterday that it will spin off its medical technology business as a separate company based in San Diego.
TRENTON, N.J., 2:38 p.m. Sept. 30 (AP)Pfizer shifts focus to cancer and biotech drugs: Pfizer Inc. is shifting its research focus to diseases that have high potential for big profits and for treatment improvements, such as cancer and Alzheimer's disease. TRENTON, N.J., 7:17 a.m. Sept. 29 (AP)
ImClone could name $70-a-share bidder on Wednesday: ImClone Systems Inc. said Monday it expects either a solid purchase proposal or formal rejection by Wednesday night from its mystery suitor, which ImClone says is offering $70 per share for the biotech company.
Sept. 27 (UNION-TRIBUNE)
Review of stem cell institute approved: The state's Little Hoover Commission, an advisory body to the governor and Legislature, said yesterday that it will examine the structure and governance of the state stem cell institute.
WASHINGTON, 10:40 a.m. Sept. 26 (AP)
FDA reviews experimental use of anemia drugs: Federal health regulators said Friday they are reviewing an experimental use of blockbuster anemia drugs made by Amgen and Johnson & Johnson that has been associated with higher death rates in a study involving stroke patients.
Sep. 26 (UNION-TRIBUNE)
Stem cell institute crafting loan plan:A new source of funding is being created for chronically cash-starved biotechnology companies. Yesterday, the California Institute for Regenerative Medicine approved the outline of a plan to set aside $500 million for loans to companies and research institutes, a lending program expected to have a high failure rate.
Sept. 25 (UNION-TRIBUNE)
Appeal plan is proposed for stem cell panel grants: When the state stem cell institute's board meets today in San Diego, it will consider creating a formal process for scientists to appeal reviews of grant applications that may contain errors that wrongly prevent them from receiving funding.
TRENTON, N.J., 11:30 a.m. Sept. 25 (AP)Wyeth: Menopause drug reduces multiple symptoms: An experimental menopause treatment drugmaker Wyeth is developing reduced hot flashes, trouble sleeping and other symptoms and did not increase breast tenderness, a problem that bothers many women taking menopause drugs, according to data from two studies released Thursday. BOSTON, 6:14 a.m. Sept. 25 (REUTERS)
Failed biotechs tout cash to attract buyers: Small biotechnology companies with cash but failed or floundering products are in hot demand as partners for companies that are unable to raise money in the capital markets.
WICHITA, Kan., 12:21 a.m. Sept. 22 (AP)
Biotech corn, soybeans encroaching on wheat acres: Biotechnology that allows more profitable corn and soybean crops to thrive in arid fields is encroaching on traditional wheat acreage across the Great Plains, industry experts say.
WASHINGTON, 1:25 p.m. Sept. 23 (REUTERS)
Hormone therapy may cut breast cancer risk in some: Hormone replacement therapy, which raises breast cancer risk for some women, appears to reduce the risk for those with a certain genetic mutation linked to the disease, researchers said Tuesday.
WASHINGTON, 1:15 p.m. Sept. 23 (REUTERS)
Tarceva makers warn of liver damage, 2 deaths: Genentech Inc and OSI Pharmaceuticals have alerted doctors about cases of liver damage among patients who took the cancer drug Tarceva in a post-approval study, U.S. regulators said Tuesday.
WASHINGTON, 1:00 p.m. Sept. 23 (REUTERS)
Study links lung drug Spiriva to heart death risk: The blockbuster inhaled lung medication Spiriva, marketed by Pfizer Incand Boehringer Ingelheim, raises the risk of heart attack, stroke and death from heart disease, researchers said Tuesday.
NEW YORK, 5:00 a.m. Sept. 22 (REUTERS)
Decision due soon on Lilly, Daiichi blood thinner: Two large drug makers, Eli Lilly and Co and Daiichi Sankyo Co Ltd, face a critical U.S. decision this week on their shared blood-clot preventer that could dramatically boost their bottom lines.
BRUSSELS, Belgium, 6:25 a.m. Sept. 18 (AP)
EU calls for update to bolster bloc's drug fight: The EU's justice chief called on EU governments on Thursday to update their joint fight against drugs, warning more needs to be done to curb the supply and demand of hard drugs such as cocaine and heroin as new drug trafficking routes to Europe emerge.
NEW YORK, 5:56 a.m. Sept. 18 (REUTERS)J&J psoriasis drug beats top-seller Enbrel in trial: Johnson & Johnson said Thursday its experimental psoriasis drug proved more effective than top-selling treatment Enbrel in a late-stage trial, was just as safe and required far fewer injections.
Sept. 17 (UNION-TRIBUNE)
$30 million for the future: There was a satisfied glint yesterday in the eyes of San Diego scientists, academics and other community leaders who have pushed for more than four years to build public support and raise funding for stem cell research across California.
Sept. 16 (UNION-TRIBUNE)
Local stem cell consortium gets $30 million gift: T. Denny Sanford, a South Dakota businessman who is one of the nation's most generous philanthropists, is putting his money behind something that is illegal in his home state: embryonic stem cell research.
Sept. 16 (UNION-TRIBUNE)Icahn raises his interest in Amylin; stock rallies: Billionaire investor Carl Icahn apparently agreed with Wall Street analysts who saw a buying opportunity after Amylin Pharmaceuticals' shares got walloped on concerns its diabetes drug causes pancreatitis.
Sep. 16 (UNION-TRIBUNE)
Icahn raises his interest in Amylin; stock rallies:Billionaire investor Carl Icahn apparently agreed with Wall Street analysts who saw a buying opportunity after Amylin Pharmaceuticals' shares got walloped on concerns its diabetes drug causes pancreatitis.
CARMEL VALLEY, Sept. 14 (UNION-TRIBUNE)
30th Hybritech reunion marks biotech's genesis: What do successful science nerds talk about at a reunion? Kids, grandkids and the industry, sure.
LONDON, 1:28 a.m. Sept. 12 (REUTERS)
Mini antibodies: biotech's next big thing?: GlaxoSmithKline Plc's head of biotech research is excited about a new generation of “slimline” antibody medicines that may be successors to current blockbusters such as Avastin and Rituxan.
Sept. 11 (UNION-TRIBUNE)
Members of Artes Medical face suit: A shareholder lawsuit filed against current and former board members of San Diego-based Artes Medical alleges that insider trading, channel stuffing and cronyism contributed to the loss of 90 percent of the company's share value in the last year.
WASHINGTON, 11:39 a.m. Sept. 11 (AP)FDA cites brain virus with Genentech, Biogen drug: Federal regualtors said Thursday one case of a deadly brain infection has been reported in a patient taking Genentech and Biogen Idec's blockbuster arthritis and cancer drug Rituxan.
NEW YORK, 6:34 a.m. Sept. 10 (AP)
Icahn says he has $70-per-share offer for Imclone: Biotechnology company ImClone Systems Inc. said Tuesday it is considering a buyout offer worth $70 per share from an unidentified large pharmaceutical company, and rejected a $60-per-share bid from Bristol-Myers Squibb Co.
CHICAGO, 7:20 a.m. Sept. 11 (REUTERS)
Allergan says Botox works on chronic migraines: Allergan Inc said Thursday that its popular Botox wrinkle-smoother worked as a treatment for adults suffering from chronic migraines, according to late-stage clinical data.
PARIS, 9:35 a.m. Sept. 10 (AP)Sanofi names Viehbacher as new CEO: Sanofi-Aventis named former GlaxoSmithKline executive Chris Viehbacher as new chief executive in a move aimed at redefining its strategy, the French drugmaker said Wednesday.
Sep. 9 (UNION-TRIBUNE)
Amylin stock continues fall in spite of favorable results:The pounding of Amylin Pharmaceuticals' stock price continued yesterday, despite the publication of positive results from an international study of the company's newest diabetes drug.
WASHINGTON, 12:07 p.m. Sept. 8 (AP)
Panel cites benefits of Pfizer osteoporosis drug: An experimental drug from Pfizer could benefit certain women with osteoporosis, federal advisers said Monday, despite concerns of side effects.
WASHINGTON, 8:31 a.m. Sept. 5 (AP)
FDA posts list of potential problem drugs: In an effort to improve communication with doctors and patients on prescription drug safety, the government Friday began posting a list of medications under investigation for potential problems.
Sept. 4 (UNION-TRIBUNE)
Medical firm Artes suing its deposed founders: Artes Medical, a San Diego company that sells a permanent filler for facial wrinkles, last week filed a lawsuit alleging that the company's founders are negligently interfering with management and operations.
WASHINGTON, 11:13 a.m. Sept. 4 (AP)FDA orders stronger warnings for 4 arthritis drugs: The Food and Drug Administration ordered stronger warnings Thursday on four medications widely used to treat rheumatoid arthritis and other serious illnesses, saying they can raise the risk of possibly fatal fungal infections. WASHINGTON, 11:10 a.m. Sept. 4 (REUTERS)
Roche hepatitis B test wins U.S. FDA approval: Roche Holding AG's DNA test is a safe and effective way to help gauge how well hepatitis B virus treatments are working, U.S. health regulators said on Thursday. CAMBRIDGE, Mass., 7:00 a.m. Sept. 4 (AP)
Broads give $400M to MIT-Harvard biomed institute: Billionaire philanthropists Eli and Edythe Broad are adding $400 million to a joint biomedical venture at Harvard and MIT. Sept. 3 (UNION-TRIBUNE)
2nd La Jolla research institute gets huge NIH grant: The modern equivalent of a help-wanted sign should be posted soon in Torrey Pines, thanks to almost $180 million in twin grants won by major research institutes from the National Institutes of Health. Sept. 2 (UNION-TRIBUNE)
Scripps gets $80 million grant: The Scripps Research Institute has been awarded more than $80 million – its largest grant ever – to be a research hub in a federally funded network that will ferret out new targets in the body that play a key role in disease.
MUNICH, Germany, 6:12 a.m. Sept. 2 (AP)
Study: No proof of Vytorin link to cancer: New research into a possible link between a cholesterol-reducing drug and cancer concluded there was no proof to establish a connection, but other doctors warned that it should be used more carefully.
LONDON, 5:55 a.m. Aug. 28 (REUTERS)
Glaxo signs deal worth up to $820 million with Valeant: GlaxoSmithKline Plc has signed a deal potentially worth up to $820 million with Valeant Pharmaceuticals International to access the U.S. company's experimental epilepsy and pain treatments.
BASEL, Switzerland, 5:30 a.m. Aug. 29 (AP)Novartis plans $235M charge after dropping drug: Swiss pharmaceutical company Novartis AG said Friday it would take a $235 million impairment charge in the next quarter after deciding to drop its development of a new antibiotic drug. LONDON, 2:12 a.m. Aug. 28 (REUTERS)
Cervical cancer advances give hope to poor: New screening tests and effective vaccines from Merck & Co and GlaxoSmithKline make tackling cervical cancer in poor countries a real possibility for the first time, researchers said on Thursday.
Aug. 27 (UNION-TRIBUNE)
Maker of diabetes drug reports four more deaths: Amylin Pharmaceuticals yesterday reported an additional four deaths among patients taking its diabetes drug Byetta, although the deaths could be attributed to other causes.
WASHINGTON, 11:18 a.m. Aug. 27 (AP)
Study outcome won't sway company on eye drug: What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
BASEL, Switzerland, 9:40 a.m. Aug. 27 (AP)Novartis drug receives funding approval: Novartis AG said Wednesday that its blindness drug Lucentis has won funding approval in England and Wales, making it freely available to tens of thousands of patients. WASHINGTON, 7:37 a.m. Aug. 26 (REUTERS)
U.S. warns Novartis generic unit on plant problems: U.S. regulators have warned Novartis AG's generic drug unit Sandoz about manufacturing problems at a North Carolina plant, a letter released Tuesday said. LA JOLLA, Aug. 25 (UNION-TRIBUNE)
Team's method a boon for stem cell research: The discovery of stem cells in teeth, menstrual blood, amniotic fluid and other sources has peppered the headlines over the past few years.
NEW YORK, 5:44 a.m. Aug. 22 (AP)
King offers $1.4 billion in cash for Alpharma: Drugmaker King Pharmaceuticals Inc. said Friday it offered Alpharma Inc. $1.4 billion in cash as part of an unsolicited buyout bid in a move to create a large diverse specialty pharmaceutical company and expand its pain therapy products.
WASHINGTON, 9:43 a.m. Aug. 22 (REUTERS)
U.S. FDA approves Amgen's blood platelet booster: Amgen Inc drug Nplate is safe and effective for treating a rare clotting disorder that can cause dangerous bleeding, the Food and Drug Administration said Friday in approving the product for U.S. sales.
Aug. 20 (UNION-TRIBUNE)
Amylin shares keep declining: Shares of Amylin Pharmaceuticals continued to drop yesterday following the Food and Drug Administration report on Monday that six people taking the company's diabetes drug developed severe pancreatitis and two of them died.
Aug. 19 (UNION-TRIBUNE)
6 people on diabetes drug fall ill; 2 die: The Food and Drug Administration yesterday reported that six people with type 2 diabetes, who were taking Amylin Pharmaceuticals' drug Byetta to control their blood sugar, developed a severe inflammation of the pancreas.
Aug. 14 (UNION-TRIBUNE)
Stem cell group awards grants to scientists at 2 universities: Six San Diego scientists will receive almost $15 million in funding from the state stem cell institute to support projects ranging from the development of a therapy to halt acute leukemias to research into therapies to prevent premature birth and birth defects.
NEW YORK, 6:57 a.m. Aug. 13 (AP)
Genentech rejects Roche's $43.7 billion bid: Biotechnology giant Genentech is turning down a buyout offer from its majority owner Roche, saying the $43.7 billion takeover bid undervalues the company.
WASHINGTON, 7:26 a.m. Aug. 8 (REUTERS)
U.S. warns of muscle harm when heart drugs combined: U.S. health officials warned the public Friday about the risk of a rare type of muscle injury seen when the cholesterol drug simvastatin is combined with the anti-arrhythmia medicine amiodarone.
Aug. 1 (UNION-TRIBUNE)Endurance lift without lifting: Couch potatoes, take heart: A team of scientists at the Salk Institute in La Jolla has made a discovery that might just make your dreams come true.
Aug. 1 (UNION-TRIBUNE)
Pair settle fraud lawsuit at SeraCare: Two former executives of SeraCare Life Sciences have settled a civil fraud lawsuit with the U.S. Securities and Exchange Commission related to an accounting scandal at the company three years ago.
Aug. 1 (UNION-TRIBUNE)
Acetavance lifts Cadence stock:Cadence Pharmaceuticals shares jumped more than 60 percent yesterday after the San Diego startup said it won't have to conduct any additional clinical trials of its developmental drug, Acetavance.
DUBLIN/LONDON, 9:07 a.m. Aug. 1 (REUTERS)
Elan, Biogen dive on MS drug safety scare: Shares in Irish drugmaker Elan Corp PLC lost half their value Friday while partner Biogen Idec tumbled 25 percent as renewed safety concerns call into question the future of their multiple sclerosis drug Tysabri.
WASHINGTON, 7:25 a.m. Aug. 1 (AP)
FDA rejects Schering drug to reverse anesthesia: Government regulators dealt a major setback to Schering-Plough Corp. Thursday, rejecting a highly anticipated drug designed to help patients recover from anesthesia.
NEW DELHI, 6:00 a.m. Aug. 1 (AP)
WHO approves 18th Ranbaxy HIV drug: Ranbaxy Laboratories Ltd., India's largest pharmaceutical company, said Friday that the World Health Organization had included another of its HIV-fighting drugs on its prequalification list.
NEW YORK, 5:44 a.m. July 31 (AP)Bristol-Myers offering $4.5 billion for ImClone: Drug developer Bristol-Myers Squibb Co. offered $4.5 billion in cash for its cancer drug partner ImClone Systems Inc. Thursday, though the biotechnology company's board has yet to comment on the proposal.
LONDON, 4:52 a.m. July 31 (AP)
Astra 2Q profit up 13 percent, outlook upbeat: Pharmaceutical company AstraZeneca PLC posted a 13 percent rise in second-quarter profit on Thursday, and increased its full-year earnings per share target as it continues to strengthen its drug pipeline.
SAN DIEGO, 12:26 p.m. July 30 (SIGNONSANDIEGO)
BIOCOM Institute wins nonprofit status and two grants: The BIOCOM Institute, a charitable arm of the BIOCOM regional association of biotech companies, announced Wednesday that it has won nonprofit status and been awarded a pair of $30,000 grants.
CHICAGO, 1:00 p.m. July 30 (REUTERS)Lilly says Alzheimer's antibody drug safe: Eli Lilly and Co's antibody drug for Alzheimer's disease was safe and appeared to be dissolving sticky brain plaques, but a three-month study was too short to show any improvement in memory, company researchers said Wednesday. SAN FRANCISCO, 12:53 p.m. July 30 (AP)
Scientists: Egg shortage hurts stem cell research: Facing a human egg shortage they say is preventing medical breakthroughs, scientists and biotech entrepreneurs are pushing the country's top funders of stem cell research to rethink rules that prohibit paying women for eggs.
CHICAGO, 10:33 a.m. July 30 (REUTERS)
Allergan profit rises but Botox sales lag: Allergan Inc said Wednesday second-quarter earnings rose, matching Wall Street's estimates, even as sales of Botox and other key products were lower than expected.
LONDON, 10:14 a.m. July 30 (REUTERS)OrbiMed tips $102-105/shr Roche bid for Genentech: Roche Holding AG is likely to sweeten its offer for Genentech Inc to between $102 and $105 a share, from $89 at present, according to a top fund manager and shareholder in the U.S. biotech group.
NEW YORK, 6:55 a.m. July 29 (REUTERS)
Sepracor profit badly misses views, shares slump: U.S. drugmaker Sepracor Inc Tuesday reported second-quarter results that badly missed analyst expectations on disappointing sales and high expenses, and the company cut its full-year revenue forecast, sending its shares down as much as 16 percent.
NEW YORK, 7:47 a.m. July 28 (REUTERS)
Amgen shares soar on bone drug: Wall Street is confident Amgen Inc will win approval for its lead experimental medicine, the osteoporosis drug denosumab, but questions remain about the drug's sales potential.
TORONTO, 8:36 a.m. July 28 (REUTERS)Biovail founder Melnyk drops board battle: Biovail Corp founder Eugene Melnyk said Monday he was abandoning his plan to oust the Canadian drugmaker's board of directors and elect his own team at Biovail's shareholders meeting next month.
July 26 (UNION-TRIBUNE)
Shares of S.D. spinal surgery company leap: Shares of NuVasive, a San Diego company that makes tools for minimally invasive spinal surgery, jumped 17 percent yesterday after it reported strong second-quarter revenue and raised its earnings projections for 2008.
July 27 (UNION-TRIBUNE)
The race against gene doping:Past controversy has not made this year's Tour de France scandal-free. Cycling's premier event, which ends today, has again been marred by busts for illegal doping, with at least three riders thrown out and entire teams quitting. The Summer Olympics begin Aug. 8, and rumors of illicit drug use are likely to be rampant there, too.
July 24 (UNION-TRIBUNE)
Gene tests raise legal and ethical questions: Do your personal genetics make it more likely that you could develop cancer or Alzheimer's disease? Or do you need a personalized nutrition plan because your genetic profile shows you are unable to absorb certain vitamins properly?
WASHINGTON, 11:48 a.m. July 24 (REUTERS)U.S. urges genetic test before using Glaxo AIDS drug: AIDS patients should have a genetic test before treatment with GlaxoSmithKline Plc's drug Ziagen to see whether they face a higher risk of a potentially fatal reaction, U.S. regulators said Thursday. WASHINGTON, 11:00 a.m. July 24 (AP)
Officials: Search for HIV vaccine needs overhaul: Scientists will have to take “enormous intellectual leaps” to develop an AIDS vaccine in the coming years, say researchers clearly frustrated by the failure of a once-promising shot. TRENTON, N.J., 10:47 a.m. July 24 (AP)
Bristol-Myers Squibb posts 8 percent profit jump: Drugmaker Bristol-Myers Squibb Co. on Thursday reported an 8 percent increase in second-quarter profit, beating Wall Street expectations, as the weak dollar boosted foreign sales and several key drugs saw big jumps in U.S. sales. Shares were up nearly 2 percent. BOSTON, 8:08 a.m. July 23 (REUTERS)
Gene tied to muscle weakness from cholesterol drugs: British researchers have located a gene responsible for muscle pain or weakness experienced by some people taking statin drugs to fight “bad” cholesterol, they reported Wednesday.
7:02 a.m. July 22 (AP)
Biogen Idec's 2Q profit rises 11 percent: A surge in multiple-sclerosis drug sales drove an 11 percent boost in Biogen Idec Inc.'s second-quarter profit, prompting the biotechnology company to boost its full-year outlook and aim for record revenue of $4 billion.
July 23 (UNION-TRIBUNE)
Illumina's bountiful day - and then some:It was an up kind of day yesterday for San Diego genetics analysis company Illumina. Its shares rose more than 4 percent in after-hours trading after the company's report of a 66 percent jump in revenue and a $6.1 million increase in quarterly profits.
BASEL, Switzerland, 7:36 a.m. July 22 (AP)Top Roche, Genentech officials meeting: Top officials of Swiss pharmaceutical giant Roche Holding and Genentech Inc. are meeting Tuesday to discuss Roche's proposed $43.7 billion takeover bid for the U.S. biotechnology pioneer. July 22 (UNION-TRIBUNE)
Diabetes drug maker Amylin posts wider second-quarter loss: The expense of developing a once-weekly version of its diabetes drug, Byetta, led to a wider second-quarter loss, Amylin Pharmaceuticals reported yesterday.
TRENTON, N.J., 8:00 a.m. July 21 (AP)
Merck and Schering delay 2Q reports to afternoon: Drugmakers Schering-Plough Corp. and Merck & Co. took the highly unusual step of delaying their second-quarter results until after the closing bell Monday so European researchers can present data from a study of the companies' cholesterol drug Vytorin.
July 17 (UNION-TRIBUNE)
Traveler's diarrhea drug said to work: A San Diego company developing an antibiotic for traveler's diarrhea said results from a late-stage clinical trial show that its product is faster and works on a broader range of gut-wrenching bacteria than those already on the market.
July 19 (UNION-TRIBUNE)
Stem cell patent ruling contested:Two consumer groups yesterday filed an appeal of a U.S. Patent and Trade Office ruling that said the University of Wisconsin's Alumni Research Foundation could maintain its patents on all embryonic stem cells used in the United States.
NEW YORK, 6:43 a.m. July 16 (REUTERS)
Abbott tops forecast: Abbott Laboratories Inc Wednesday said second-quarter earnings jumped 34 percent, beating its expectations, fueled by sizzling sales of its medical devices, Humira arthritis treatment and other drugs.
CHICAGO, 5:21 a.m. July 16 (REUTERS)St. Jude Medical earnings rise: St. Jude Medical Inc on Wednesday said quarterly earnings rose 55 percent, beating Wall Street estimates, as sales of its implantable cardioverter defibrillators, or ICDs, rebounded from a year earlier.
BRANFORD, Conn., 4:40 a.m. July 14 (AP)
Neurogen stops adipiplon trial due to side effects: Biotechnology company Neurogen Corp. said Sunday it stopped a clinical trial of its insomnia candidate adipiplon because of negative side effects.
July 10 (UNION-TRIBUNE)
Gen-Probe bows to higher bid by rival for Belgian biotech: San Diego medical diagnostics giant Gen-Probe declined yesterday to increase its June 3 offer for a Belgian biotechnology company after a European rival topped its $297 million bid with a higher offer.
July 10 (UNION-TRIBUNE)
Scientists: 'Gene wiki' could decode genome faster: Unraveling the mysteries of the human genome, the chain of chemicals that determine everything from a person's hair color to predisposition toward cancer, is a mammoth undertaking.
NEW YORK, 10:54 a.m. July 10 (REUTERS)
New U.S. drug marketing code draws line at gift pens: Come next year, doctors may start to see a problem they've yet to experience – a pen shortage.
WASHINGTON, 7:58 a.m. July 9 (REUTERS)
U.S. FDA changing notices on drug decisions: U.S. regulators will change the way they tell drugmakers that their medicines are not ready to be approved, the Food and Drug Administration said Wednesday.
WASHINGTON, 8:20 a.m. July 9 (AP)
U.S., Europe, Australia to expand drug inspections: Faced with the globalization of drug production, the United States is joining with Europe and Australia to inspect factories in China and India that make raw materials for medications.
July 9 (UNION-TRIBUNE)
Invitrogen wins approval for cancer-gene drug test: A test made by Invitrogen that can determine whether women with breast cancer could be helped by taking the powerful drug Herceptin was approved yesterday by the Food and Drug Administration.
July 9 (UNION-TRIBUNE)Lilly to buy biotech SGX in $64 million cash deal: Eli Lilly and Co. said yesterday that it will acquire SGX Pharmaceuticals in a $64 million cash deal that will pay shareholders in the San Diego biotech a substantial premium.
WASHINGTON, 5:56 a.m. July 8 (REUTERS)
FDA OK's Invitrogen genetic test for breast cancer: The U.S. Food and Drug Administration said Tuesday it approved Carlsbad-based Invitrogen Corp's genetic test for determining whether patients with breast cancer are good candidates for treatment with the drug Herceptin.
July 8 (UNION-TRIBUNE)Pa. company will acquire S.D.'s Inovio in reverse merger: Inovio Biomedical Corp., a San Diego company that developed technology for electrically charging cells to make them more porous for drugs to enter, said yesterday that it will be acquired in a reverse merger with VGX Pharmaceuticals, a privately held company developing DNA vaccines. WASHINGTON, 10:45 a.m. July 7 (REUTERS)
FDA to urge black box warning for epilepsy drugs: Food and Drug Administration officials will seek a strong “black box” warning for epilepsy drugs cautioning about the risk of suicidal thoughts and behavior, an agency spokeswoman told Reuters Monday.
July 6 (UNION-TRIBUNE)
Stem cell grant review upsets some applicants: The state's stem cell institute, which so far has approved $554 million in taxpayer-funded research grants, is basing its funding decisions on recommendations from panels of scientists who sometimes make significant factual errors in their reviews of grant requests, some applicants say.
June 28 (UNION-TRIBUNE)
S.D. stem cell efforts awarded $5 million total: San Diego scientists were awarded $5 million in grants yesterday from a pool of $24 million approved by the California Institute for Regenerative Medicine.
June 25 (UNION-TRIBUNE)
Repairing damage to brain may be nearer: SAN DIEGO – A team of San Diego scientists has moved embryonic stem cell research a step closer to helping repair the brains of stroke victims and people with diseases such as Parkinson's and Alzheimer's.
June 24 (UNION-TRIBUNE)
Report defends drug companies: Answering critics who accuse drug companies of reaping obscene financial reward for little that is innovative, a conservative think tank investigated how the companies turned publicly funded science into therapies for cancer, hypertension and arthritis.
June 20 (UNION-TRIBUNE)Biotechs now welcoming patient-advocacy funds: With all the panel discussions at the Biotechnology Industry Organization's annual convention about ways to get funding for drug discovery, it is hard to believe that Robert Beall, chief executive of the Cystic Fibrosis Foundation, once had a hard time giving money away.
June 19 (UNION-TRIBUNE)
Governor lauds bio's 'brain power': Gov. Arnold Schwarzenegger yesterday lauded the world's biotechnology industry for tackling a pile of complicated issues – therapies for disease, diagnostics to improve health care and alternative fuels that may one day create “a carbon-free world.”
June 19 (UNION-TRIBUNE)
Biotechs fight bulge: Good news for the overweight: Three San Diego biotechnology companies say the battle with the bulge is about chemicals in your body, not just a lack of will to exercise and cut calories. Amylin Pharmaceuticals, Arena Pharmaceuticals and Orexigen Therapeutics are among about 20 companies that are developing drugs to treat obesity.
June 19 (UNION-TRIBUNE)
Big Pharma generous with big swag: Santa Monica's Ye Ye has lofty ambitions. One of these days, the microbiologist would like to defeat the SARS virus. Yesterday at the BIO International Convention downtown, though, her goal was more down-to-earth: a pair of Crocs. Size 6. Free.
June 18 (UNION-TRIBUNE)Biotech bandwagon: Across the country, states are investing billions of dollars to fuel scientific research and create biotechnology hubs like those in California, which has the world's largest concentration of biotechnology companies and investment. On Monday, Massachusetts signed into law a $1 billion incentive package to ignite biotechnology development under a proposal Gov. Deval Patrick revealed a year ago.
June 18 (UNION-TRIBUNE)
Turning personalized medicine into reality: It's been a hot couple of years for genomics, the study of the long chain of chemicals that determines all the hereditary information in a person's DNA, from hair and eye color to propensity for disease.
NEW YORK, 6:29 a.m. June 18 (REUTERS)
Pfizer, Ranbaxy deal would delay generic Lipitor: Pfizer Inc said Wednesday that Ranbaxy Laboratories Ltd can begin selling a U.S. generic form of its Lipitor cholesterol fighter by late 2011 under a settlement deal, some five months later than Wall Street expectations.
June 17 (UNION-TRIBUNE)Biology reborn: The word “biotechnology” conjures some intimidating images of people in white lab coats working with test tubes, and maybe expensive robotic equipment, that somehow magically results in the creation of new drugs.
June 17 (UNION-TRIBUNE)
Plowing ahead on biofuel research: Ethanol from corn is yesterday's news, though you might not know it from the headlines and congressional hearings blaming the alternative fuel for rising food prices and disappearing rain forests.
June 17 (UNION-TRIBUNE)
China boosts biotech: PacificGMP, a tiny local manufacturer of biotechnology drugs, will announce today that it is expanding to 25 times its size with the help of the Chinese government. The company, which has an 8,000-square-foot facility in Sorrento Mesa for manufacturing biological agents used in cutting-edge therapies for disease, will join a collaboration that is building a 200,000-square-foot plant in Taizhou, China.
June 17 (UNION-TRIBUNE)
Schizophrenia drug by Acadia will be scrapped: Acadia Pharmaceuticals shares plummeted more than 40 percent yesterday after the San Diego company announced that its experimental schizophrenia drug failed in a midstage clinical trial.
June 17 (UNION-TRIBUNE)
Building a brain bank: Leave your baking-soda volcanoes and rubber-band balls at home. Collaborators for the San Diego Science Festival say they'd like to ignite the scientific impulse within school-age children and eventually refurbish a dwindling supply of U.S. scientists. The event, planned for next spring, will be no cafeteria-style science fair but rather a jumbo, weekend-long expo preceded by a monthlong series of kid-friendly events involving perhaps 1,000 scientific organizations, companies, universities and Nobel laureates.
June 17 (UNION-TRIBUNE)
It all adds up : After working in the hotel and mortgage industries, Jami Martinsen moved into biotech in June 2005 when she joined the finance team at the San Diego company Gen-Probe.
June 17 (UNION-TRIBUNE)
A beam of hope: Tony Grover is working to make sure a new treatment for stroke victims qualifies as “reasonable and necessary” under government standards. Grover, who works at the Carlsbad company PhotoThera, says the current treatment for stroke works best if patients get treatment within three hours.
June 17 (UNION-TRIBUNE)
A validating experience: An interest in science is what got Greg Budahazi started in the biotech industry. After graduating from UCSD with a bachelor's degree in biochemistry, he began his biotech career in San Diego in the mid '80s, working in research and development.
June 17 (UNION-TRIBUNE)
After impact :
Mary Bauman joined the team at Amylin Pharmaceuticals six months ago and moved to San Diego from the Bay Area, where she had worked for Bayer for 17 years.
June 17 (UNION-TRIBUNE)
Giving biotech a spin:
Leigh Amini had no intention of getting into the biotech industry. In fact, she was going to college to become a teacher when a job in administration led her down a different path.
SAN DIEGO, June 16 (UNION-TRIBUNE)
UCSD study: DHEA not beneficial: Healthy seniors who take DHEA tablets to protect memory or pep up their sex lives are wasting money, according to a yearlong UCSD study that found no gains from the over-the-counter hormone supplement.
June 15 (UNION-TRIBUNE)Culture clash: San Diego attained its position as home to the world's third-largest concentration of biotechnology companies through its volume of small firms. June 15 (UNION-TRIBUNE)
BIO chief talks about industry's concerns: The biotechnology industry considers funding for the Food and Drug Administration and the National Institutes of Health, as well as rules for making generic drugs, as its top political issues this year, said James Greenwood, who heads the national Biotechnology Industry Organization. June 15 (UNION-TRIBUNE)
Biotech breakthroughs: Dave Christensen got the bad news five years ago: The lump in his neck was non-Hodgkin's lymphoma, a cancer of the blood and lymphatic system.
June 13 (UNION-TRIBUNE)
Invitrogen to buy Applied, creating a biotech giant: Invitrogen, a Carlsbad company started in its founder's garage in 1987, will become one of the world's largest biotechnology companies with its acquisition yesterday of scientific instrument maker Applied Biosystems Inc.
BASEL, Switzerland, 6:50 a.m. June 13 (AP)Glivec misses target in clinical study: Clinical trials have failed to show that a cancer drug made by Novartis is more effective in higher doses, the pharmaceutical company said Friday. WASHINGTON, 7:22 a.m. June 13 (AP)
FDA may require cancer-risk labeling on J&J drug: An experimental drug from a unit of Johnson & Johnson appears effective at treating a severe skin disease, though government regulators said Friday it also could slightly increase cancer risks.
CARLSBAD, 6:55 a.m. June 12 (AP)
Invitrogen to buy Applied Biosystems for $6.4B: Invitrogen has agreed to pay $6.4 billion in cash and stock for Applera's Applied Biosystems Group, the companies said Thursday.
June 11 (UNION-TRIBUNE)
Amylin gets a boost as latest drug weighs in: Amylin Pharmaceuticals' shares rebounded yesterday after the San Diego company released positive results for the once-weekly version of its diabetes drug, Byetta.
NEW YORK, 5:26 a.m. June 10 (REUTERS)
Mylan inks supply deal for generic of Teva MS drug: Mylan Inc said Tuesday it signed a licensing and supply deal for a generic version of Teva Pharmaceutical Industries Ltd's big-selling Copaxone multiple sclerosis treatment, and Teva shares fell nearly 3 percent.
LONDON, 2:43 a.m. June 11 (REUTERS)Glaxo axes 350 jobs in overhaul of drug research: GlaxoSmithKline Plc is axing around 350 jobs in research and development as part of an ongoing restructuring programme, Europe's biggest drugmaker said on Wednesday. NEW YORK, 3:01 p.m. June 10 (REUTERS)
J&J, Schering arthritis drug effective in trials: An experimental treatment for rheumatoid arthritis being developed by Johnson & Johnson and Schering-Plough Corp appeared to be effective and very safe in three late-stage trials, the companies said Tuesday. LOS ANGELES, 10:56 a.m. June 10 (REUTERS)
Roche, Ipsen launch pivotal trial of diabetes drug: Roche Holding AG and Ipsen SA said Monday they plan to launch a pivotal trial of experimental diabetes drug taspoglutide after it was shown to improve blood sugar control in a mid-stage trial.
NEW YORK, 9:54 a.m. June 9 (REUTERS)
Interim data positive on Vertex hepatitis C drug: Vertex Pharmaceuticals Inc Monday reported positive interim results from a mid-stage study of its closely watched experimental hepatitis C medicine in patients who failed to respond to prior treatment, sending its shares up 4 percent.
June 5 (UNION-TRIBUNE)
Sequenom shares soar on results: Shares of San Diego genetics analysis company Sequenom jumped more than 20 percent yesterday after the company reported its noninvasive prenatal test to screen maternal blood for Down syndrome was effective in all samples, exceeding analysts' expectations.
WASHINGTON, 10:19 a.m. June 5 (REUTERS)
Wyeth heartworm drug makes limited return in U.S.: Wyeth will return its Proheart 6 heartworm drug for dogs to the U.S. market with restrictions to minimize side effects, U.S. health officials said Thursday.
ZURICH, 12:24 a.m. June 4 (REUTERS)
Novartis buys drug firm Protez for up to $400 million: Novartis AG has bought privately held U.S. biotech company Protez Pharmaceuticals in a deal worth up to $400 million, giving it rights to an antibiotic which could be used to fight superbugs such as MRSA.
| Sponsored Links | ||
|
|
